When CAR-T became the only option — but wasn't available at home
After two lines of therapy failed, his oncologist mentioned CAR-T — but in New Zealand it wasn't funded for his subtype, and private treatment abroad was the only path. China's CAR-T programs, with over 600 clinical trials active nationwide, offered a specific construct targeting his tumor marker. Treatment was completed in 6 weeks including preparatory chemotherapy, cell collection, manufacturing, infusion, and monitoring.
"I was out of options at home. China wasn't on my radar — until it was the only place that said yes."





